The Curbsiders Internal Medicine Podcast
#477 Hotcakes: Suzetrigine for acute pain, SGLT2i and PAD, Safety of Lowering LDL, Restrictive vs Liberal Transfusion Strategy in MI revisited
Mar 31, 2025
Molly Brett, a primary care physician and associate editor for NEJM Journal Watch, joins the hosts to discuss groundbreaking findings in medical practice. They dive into the cognitive safety of very low LDL levels, raising intriguing questions. The podcast also explores suzetrogine as a promising non-opioid option for acute pain. Additionally, they evaluate the safety of SGLT2 inhibitors, linking them to peripheral artery disease. Finally, a debate unfolds over restrictive versus liberal transfusion strategies in acute myocardial infarction, shedding light on their long-term implications.
49:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Recent studies confirm that very low LDL cholesterol levels are cognitively safe, alleviating concerns about cognitive decline in high-risk patients.
- Suzetrogene shows promising results for pain management post-surgery, but more extensive studies are needed to confirm its efficacy and safety.
Deep dives
Cognitive Safety of Low LDL Levels
The discussion emphasizes the cognitive safety of achieving very low LDL cholesterol levels through the use of PCSK9 inhibitors like Evolocumab. Concerns regarding potential cognitive decline associated with significantly lowered LDL levels have been prevalent, especially when combined with statin therapy. However, recent findings indicate that no cognitive impairment has been observed in patients over a five-year follow-up period, reinforcing the idea that very low LDL levels might be safe in this context. The study helps alleviate anxieties around cognitive side effects in patients being treated for high cardiovascular risk.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
